泽璟制药：注射用ZG006与依托泊苷及顺铂联用获临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for a clinical trial of ZG006 in combination with Etoposide and Cisplatin for advanced neuroendocrine carcinoma [1] Group 1: Company Information - The drug ZG006 is specified for injection and has a dosage of 5mg per vial [1] - The applicants for the clinical trial approval include Suzhou Zelgen Biopharmaceutical Co., Ltd. and Shanghai Zelgen Pharmaceutical Technology Co., Ltd. [1] Group 2: Clinical Trial Approval - The approval allows the company to conduct a clinical trial using ZG006 in conjunction with Etoposide and Cisplatin for patients with advanced neuroendocrine carcinoma [1] - The approval is noted to have no significant impact on the company's recent performance [1] Group 3: Research and Development Considerations - The drug development process is characterized by a long timeline, multiple approval stages, and substantial research investment, which introduces uncertainty [1]